Stanford researchers have developed one of the smallest, active translational enhancers that can be adapted to control gene regulation. The translation enhancer is a short RNA stem-loop structure isolated from a Hox gene.
Stanford researchers have found a solution to enhance mRNA translation and stability by harnessing SARS-CoV2 genomic sequences themselves. They discovered that the SARS-CoV2 5' untranslated region (5' UTR) can be repurposed for increased translation and stability of any mRNA.
Stanford researchers have discovered that ribonucleoside vanadyl complexes can be used as an additive in transcription reactions resulting in ~2-fold increased yield.
A novel method for dissociating plant tissues for biochemical and genomic analysis that accommodates harsher digestion conditions with increased tissue dissociation efficiency and quality of isolated RNA.
Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).
Stanford researchers have formulated a risk scoring calculator using a human induced pluripotent stem cell (iPSC) model to accurately predict and calculate insulin resistance via a novel blood test.
Researchers at Stanford have discovered that treatment with JNK II inhibitor and IBMX has a synergistic therapeutic effect against osteoarthritis (OA).
Stanford researchers at the Chichilnisky lab have developed a novel framework for a far superior artificial retina with strikingly near optimal efficiency (96%) of visual perception.
Stanford researches have formulated a robust database called PRECOG (Prediction of Clinical Outcomes from Genomics) that connects cancer genome expression and patient survival/outcomes in a more predictive and extensive collection than any other signature on the market.
Aging is associated with the decline of mitochondrial function, particularly in related metabolic diseases such as obesity, diabetes, and heart disease.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.